Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 13/20 | 0.45 |
| ▸ | JAK3 | P52333 | 12/20 | 0.45 |
| ▸ | JAK1 | P23458 | 11/20 | 0.45 |
| ▸ | STAT3 | P40763 | 5/20 | 0.45 |
| ▸ | TYK2 | P29597 | 4/20 | 0.45 |
| ▸ | ABL1 | P00519 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.43 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15059530 | 1.00 | JAK2 (0.45) | JAK2JAK3JAK1STAT3TYK2 | |
| SCHEMBL15059211 | 0.87 | JAK3 (0.43) | JAK2JAK3JAK1AURKBPRKCQ | |
| SCHEMBL15059213 | 0.87 | JAK3 (0.43) | JAK2JAK3JAK1AURKBPRKCQ | |
| SCHEMBL15058844 | 0.86 | JAK3 (0.45) | JAK2JAK3JAK1 | |
| SCHEMBL15058843 | 0.86 | JAK3 (0.45) | JAK2JAK3JAK1 | |
| SCHEMBL15058429 | 0.84 | JAK1 (0.53) | JAK2JAK3JAK1TYK2 | |
| SCHEMBL15058430 | 0.84 | JAK1 (0.53) | JAK2JAK3JAK1TYK2 | |
| SCHEMBL16337534 | 0.84 | JAK3 (0.45) | JAK2JAK3JAK1STAT3TYK2 | |
| SCHEMBL16336319 | 0.84 | JAK3 (0.45) | JAK2JAK3JAK1STAT3TYK2 | |
| SCHEMBL15072073 | 0.84 | JAK2 (0.43) | JAK2JAK3JAK1STAT3TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150005281-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2015-01-01 | — | — | US | claimed |
| US-20150005281-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2015-01-01 | — | — | US | disclosed |
| EP-2794598-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS | Cellzome Limited (GB) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013092854-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005281-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS | JAK2, JAK1, JAK3 | JAK2 1/4885JAK3 3/4885JAK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.